Global Latanoprost for Open-angle Glaucoma 麻豆原创 Growth 2024-2030

Publication ID:

LPI08246326

Publication Date:

August 9, 2024

Pages:

103

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Latanoprost is a medication used in the treatment of open-angle glaucoma and ocular hypertension. It belongs to a class of drugs known as prostaglandin analogs. These medications work by reducing intraocular pressure (IOP) within the eye by increasing the outflow of aqueous humor, the fluid that nourishes and maintains the eye's shape. By lowering IOP, latanoprost helps to prevent damage to the optic nerve and vision loss associated with conditions like open-angle glaucoma.
The global Latanoprost for Open-angle Glaucoma market size is projected to grow from US$ 1078 million in 2024 to US$ 1335 million in 2030; it is expected to grow at a CAGR of 3.6% from 2024 to 2030.
The 鈥淟atanoprost for Open-angle Glaucoma Industry Forecast鈥� looks at past sales and reviews total world Latanoprost for Open-angle Glaucoma sales in 2023, providing a comprehensive analysis by region and market sector of projected Latanoprost for Open-angle Glaucoma sales for 2024 through 2030. With Latanoprost for Open-angle Glaucoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Latanoprost for Open-angle Glaucoma industry.
This Insight Report provides a comprehensive analysis of the global Latanoprost for Open-angle Glaucoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Latanoprost for Open-angle Glaucoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Latanoprost for Open-angle Glaucoma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Latanoprost for Open-angle Glaucoma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Latanoprost for Open-angle Glaucoma.
United States market for Latanoprost for Open-angle Glaucoma is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Latanoprost for Open-angle Glaucoma is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Latanoprost for Open-angle Glaucoma is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Latanoprost for Open-angle Glaucoma players cover Pfizer, Mylan, Novartis, Apotex, Teva, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Latanoprost for Open-angle Glaucoma market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Brand Drug
Generic Drug
Segmentation by Application:
Male Patients
Female Patients
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer
Mylan
Novartis
Apotex
Teva
Taj Pharma
CR Zizhu
Jiangsu Hengrui Pharmaceuticals
China Medical System Holdings
Key Questions Addressed in this Report
What is the 10-year outlook for the global Latanoprost for Open-angle Glaucoma market?
What factors are driving Latanoprost for Open-angle Glaucoma market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Latanoprost for Open-angle Glaucoma market opportunities vary by end market size?
How does Latanoprost for Open-angle Glaucoma break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Latanoprost for Open-angle Glaucoma Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Latanoprost for Open-angle Glaucoma by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Latanoprost for Open-angle Glaucoma by Country/Region, 2019, 2023 & 2030
2.2 Latanoprost for Open-angle Glaucoma Segment by Type
2.2.1 Brand Drug
2.2.2 Generic Drug
2.3 Latanoprost for Open-angle Glaucoma Sales by Type
2.3.1 Global Latanoprost for Open-angle Glaucoma Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Latanoprost for Open-angle Glaucoma Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Latanoprost for Open-angle Glaucoma Sale Price by Type (2019-2024)
2.4 Latanoprost for Open-angle Glaucoma Segment by Application
2.4.1 Male Patients
2.4.2 Female Patients
2.5 Latanoprost for Open-angle Glaucoma Sales by Application
2.5.1 Global Latanoprost for Open-angle Glaucoma Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Latanoprost for Open-angle Glaucoma Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Latanoprost for Open-angle Glaucoma Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Latanoprost for Open-angle Glaucoma Breakdown Data by Company
3.1.1 Global Latanoprost for Open-angle Glaucoma Annual Sales by Company (2019-2024)
3.1.2 Global Latanoprost for Open-angle Glaucoma Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Latanoprost for Open-angle Glaucoma Annual Revenue by Company (2019-2024)
3.2.1 Global Latanoprost for Open-angle Glaucoma Revenue by Company (2019-2024)
3.2.2 Global Latanoprost for Open-angle Glaucoma Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Latanoprost for Open-angle Glaucoma Sale Price by Company
3.4 Key Manufacturers Latanoprost for Open-angle Glaucoma Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Latanoprost for Open-angle Glaucoma Product Location Distribution
3.4.2 Players Latanoprost for Open-angle Glaucoma Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Latanoprost for Open-angle Glaucoma by Geographic Region
4.1 World Historic Latanoprost for Open-angle Glaucoma 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Latanoprost for Open-angle Glaucoma Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Latanoprost for Open-angle Glaucoma Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Latanoprost for Open-angle Glaucoma 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Latanoprost for Open-angle Glaucoma Annual Sales by Country/Region (2019-2024)
4.2.2 Global Latanoprost for Open-angle Glaucoma Annual Revenue by Country/Region (2019-2024)
4.3 Americas Latanoprost for Open-angle Glaucoma Sales Growth
4.4 APAC Latanoprost for Open-angle Glaucoma Sales Growth
4.5 Europe Latanoprost for Open-angle Glaucoma Sales Growth
4.6 Middle East & Africa Latanoprost for Open-angle Glaucoma Sales Growth
5 Americas
5.1 Americas Latanoprost for Open-angle Glaucoma Sales by Country
5.1.1 Americas Latanoprost for Open-angle Glaucoma Sales by Country (2019-2024)
5.1.2 Americas Latanoprost for Open-angle Glaucoma Revenue by Country (2019-2024)
5.2 Americas Latanoprost for Open-angle Glaucoma Sales by Type (2019-2024)
5.3 Americas Latanoprost for Open-angle Glaucoma Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Latanoprost for Open-angle Glaucoma Sales by Region
6.1.1 APAC Latanoprost for Open-angle Glaucoma Sales by Region (2019-2024)
6.1.2 APAC Latanoprost for Open-angle Glaucoma Revenue by Region (2019-2024)
6.2 APAC Latanoprost for Open-angle Glaucoma Sales by Type (2019-2024)
6.3 APAC Latanoprost for Open-angle Glaucoma Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Latanoprost for Open-angle Glaucoma by Country
7.1.1 Europe Latanoprost for Open-angle Glaucoma Sales by Country (2019-2024)
7.1.2 Europe Latanoprost for Open-angle Glaucoma Revenue by Country (2019-2024)
7.2 Europe Latanoprost for Open-angle Glaucoma Sales by Type (2019-2024)
7.3 Europe Latanoprost for Open-angle Glaucoma Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Latanoprost for Open-angle Glaucoma by Country
8.1.1 Middle East & Africa Latanoprost for Open-angle Glaucoma Sales by Country (2019-2024)
8.1.2 Middle East & Africa Latanoprost for Open-angle Glaucoma Revenue by Country (2019-2024)
8.2 Middle East & Africa Latanoprost for Open-angle Glaucoma Sales by Type (2019-2024)
8.3 Middle East & Africa Latanoprost for Open-angle Glaucoma Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Latanoprost for Open-angle Glaucoma
10.3 Manufacturing Process Analysis of Latanoprost for Open-angle Glaucoma
10.4 Industry Chain Structure of Latanoprost for Open-angle Glaucoma
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Latanoprost for Open-angle Glaucoma Distributors
11.3 Latanoprost for Open-angle Glaucoma Customer
12 World Forecast Review for Latanoprost for Open-angle Glaucoma by Geographic Region
12.1 Global Latanoprost for Open-angle Glaucoma 麻豆原创 Size Forecast by Region
12.1.1 Global Latanoprost for Open-angle Glaucoma Forecast by Region (2025-2030)
12.1.2 Global Latanoprost for Open-angle Glaucoma Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Latanoprost for Open-angle Glaucoma Forecast by Type (2025-2030)
12.7 Global Latanoprost for Open-angle Glaucoma Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Latanoprost for Open-angle Glaucoma Product Portfolios and Specifications
13.1.3 Pfizer Latanoprost for Open-angle Glaucoma Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Mylan
13.2.1 Mylan Company Information
13.2.2 Mylan Latanoprost for Open-angle Glaucoma Product Portfolios and Specifications
13.2.3 Mylan Latanoprost for Open-angle Glaucoma Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Mylan Main Business Overview
13.2.5 Mylan Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis Latanoprost for Open-angle Glaucoma Product Portfolios and Specifications
13.3.3 Novartis Latanoprost for Open-angle Glaucoma Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Apotex
13.4.1 Apotex Company Information
13.4.2 Apotex Latanoprost for Open-angle Glaucoma Product Portfolios and Specifications
13.4.3 Apotex Latanoprost for Open-angle Glaucoma Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Apotex Main Business Overview
13.4.5 Apotex Latest Developments
13.5 Teva
13.5.1 Teva Company Information
13.5.2 Teva Latanoprost for Open-angle Glaucoma Product Portfolios and Specifications
13.5.3 Teva Latanoprost for Open-angle Glaucoma Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Teva Main Business Overview
13.5.5 Teva Latest Developments
13.6 Taj Pharma
13.6.1 Taj Pharma Company Information
13.6.2 Taj Pharma Latanoprost for Open-angle Glaucoma Product Portfolios and Specifications
13.6.3 Taj Pharma Latanoprost for Open-angle Glaucoma Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Taj Pharma Main Business Overview
13.6.5 Taj Pharma Latest Developments
13.7 CR Zizhu
13.7.1 CR Zizhu Company Information
13.7.2 CR Zizhu Latanoprost for Open-angle Glaucoma Product Portfolios and Specifications
13.7.3 CR Zizhu Latanoprost for Open-angle Glaucoma Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 CR Zizhu Main Business Overview
13.7.5 CR Zizhu Latest Developments
13.8 Jiangsu Hengrui Pharmaceuticals
13.8.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.8.2 Jiangsu Hengrui Pharmaceuticals Latanoprost for Open-angle Glaucoma Product Portfolios and Specifications
13.8.3 Jiangsu Hengrui Pharmaceuticals Latanoprost for Open-angle Glaucoma Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.8.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.9 China Medical System Holdings
13.9.1 China Medical System Holdings Company Information
13.9.2 China Medical System Holdings Latanoprost for Open-angle Glaucoma Product Portfolios and Specifications
13.9.3 China Medical System Holdings Latanoprost for Open-angle Glaucoma Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 China Medical System Holdings Main Business Overview
13.9.5 China Medical System Holdings Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.